Cannabis stocks tend to get fresh attention on April 20 – Cannabis Day – yet the latest view on Tilray Brands (TLRY) is more balanced than bullish. Spark, TipRanks’ AI analyst, assigns the stock a Neutral rating of 49, with a price target of $7, implying about 2% upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The rating reflects a mix of solid business progress and ongoing financial pressure. While the company is showing growth in key areas, it still faces limits tied to cash flow and profit.
Meanwhile, TLRY shares rose over 1% on Friday, closing the day at $6.86. However, the stock is down 24% year-to-date.
Strong Growth in Key Segments
First, Tilray delivered a solid earnings report at the start of April for its fiscal third quarter of 2026. Revenue reached $206.7 million, up 11% from a year ago, which marked a record for the quarter. At the same time, adjusted EBITDA rose 19% to $10.7 million, showing better cost control and scale.
In addition, the company saw strong momentum in the international cannabis market. Sales in that segment grew 73% year-over-year, helped by higher demand for medical products. Management noted that medical cannabis flower volume rose 100% while oil volume increased 90%, indicating rising demand in regulated markets.
Growth in Europe remains a key driver. Germany, for example, posted 43% growth during the quarter. This trend helps Tilray reduce its reliance on the U.S. market, where rules remain uncertain.
At the same time, Tilray’s distribution business also stood out. Revenue from this segment rose 35% to $83 million, supported by new partnerships and a wider pharmacy network in Europe.
Cash Flow and Profit Still Weigh on the Stock
However, the rating stays neutral because the company is still not profitable on a full basis. Tilray continues to report large net losses and negative free cash flow. Over the trailing period, free cash flow was about $95.7 million negative, indicating the business is still using cash rather than generating it.
Even in the latest quarter, Tilray produced $3.4 million in operating cash before working capital, yet used $21.9 million after those changes. This gap signals that the company still depends on outside funding or balance sheet moves to support growth.
The AI model points to this issue clearly. It notes that “the business remains cash-burning and not self-funding,” which can limit flexibility and raise the risk of share dilution over time.
Meanwhile, Tilray’s beverage segment also remains under pressure. Revenue in that unit declined compared to last year, and margins fell due to higher input costs like aluminum and fuel. While management is working to improve this through cost savings and pricing actions, the segment is still in a transition phase.
A Balanced Outlook for Investors
Looking ahead, Tilray reaffirmed its full-year adjusted EBITDA guidance of $62 million to $72 million, supported by cost savings under its Project 420 plan and steady demand in core markets.
The company also ended the quarter with about $264.8 million in cash and marketable securities, which gives it a solid liquidity base for now.
Still, the broader picture remains mixed. Tilray is growing revenue and expanding its global reach, especially in Europe. At the same time, it has not yet reached steady profitability or positive free cash flow.
In short, the AI view reflects this balance. Tilray shows real progress as an operating business, yet the financial results still need to catch up. Until that gap closes, the stock remains in a wait-and-see zone for many investors.
Is TLRY Stock a Good Buy?
Turning to the Street, Tilray Brands holds a Moderate Buy consensus, based on five ratings issued in the last three months. The average TLRY stock price target is $7.98, which implies a 16.33% upside from the current price.
